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Bupropion is an antidepressant and smoking cessation aid that is extensively metabolized 
by cytochrome P450 (CYP) 2B6. It is a highly lipophilic chiral drug that undergoes 
stereoselective metabolism with preference for the (S)-enantiomer. Despite chemical reasons for 
why bupropion can be metabolized by other CYP isozymes, clinically, bupropion is 
preferentially metabolized by CYP2B6, and at certain concentrations, CYP2E1, CYP2C19, and 
CYP3A4. A computational analysis with simulated molecular docking was performed using two 
different scoring algorithms to analyze the specific amino acid interactions between bupropion 
and various CYP isozymes. Trials were run using one stereoisomer of bupropion (R- or S-) and a 
panel of nine human drug metabolizing CYP enzymes: CYP1A2, CYP2A6, CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. The location of ligand binding was 
observed, and interactions between the ligand and enzyme active site residues and heme group 
were defined as residues within 5 Å of the ligand. In silico docking experiments revealed that in 
some isozymes, bupropion did not bind close enough to the heme for metabolism (CYP2C9), had 
the site of CYP enzyme metabolism away from the heme iron (CYP2D6), had many steric 
clashes (CYP2E1), or had a mix of these issues (CYP2C19). However, differences in binding 
alone do not fully explain the CYP2B6 selective bupropion metabolism.  
Introduction 
An antidepressant is a first-line treatment option for patients with mild to moderate and 
severe major depressive disorder. With the effectiveness of different antidepressants being 
generally comparable, the choice is based on side effects and patient tolerability.1 Optimal 
choices for patients include norepinephrine-dopamine reuptake inhibitors like bupropion. It 
works by decreasing presynaptic reuptake of norepinephrine and dopamine to increase their 
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concentrations in the synapse. It is comparable to selective serotonin reuptake inhibitors without 
the sympathomimetic and anticholinergic properties of tricyclic antidepressants.2 It is well-
tolerated with side effects including tachyarrhythmia, constipation, nausea, headache, insomnia, 
and xerostomia. Bupropion is also FDA-approved as a second-line treatment option for smoking 
cessation for individuals with cardiovascular disease who have contraindications to the first-line 
treatment options.3 Bupropion relieves the effects of nicotine withdrawal as a norepinephrine-
dopamine reuptake inhibitor.  It is a widely used medication in the United States. According to 
ClinCalc, there were 24,903,971 prescriptions for bupropion in the United States in 2017, 
making it the twenty-third most commonly prescribed medication of that year.4 
As a common drug, it is critical to identify key adverse effects and drug-drug 
interactions. There have been rare reports of association with seizure and allergic reactions, 
making seizure disorders a contraindication for bupropion. The body must properly metabolize 
bupropion because otherwise, bupropion concentrations can accumulate in the body and further 
lower seizure thresholds. Bupropion is also a potent inhibitor of CYP2D6, creating a need for 
caution when dosing bupropion with substrates of CYP2D6. For example, clinical studies have 
found a five-fold increase in desipramine exposure, an antidepressant, when co-administered 
with bupropion.5 Another study used physiologically-based pharmacokinetic (PBPK) models to 
predict the drug-drug interactions between bupropion and various CYP2D6 substrates, such as 
venlafaxine, bufuralol, tolterodine, metoprolol, and dextromethorphan, which all increased in 
concentration.5  In the case of metoprolol, a beta-blocker, increased concentrations could lead to 
a serious adverse event like severe bradycardia, as suggested in a case report.5 For the mentioned 
substrates, either bupropion or its metabolites inhibited CYP2D6 catalysis. Consequently, it 
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would be important to understand how bupropion is metabolized and what metabolites are 
formed.  
Additionally, genetic polymorphisms of CYP2B6 have affected the effectiveness of 
bupropion as a smoking cessation aid.6 A genetic polymorphism in CYP2B6 could indicate a 
lower dose for bupropion for these reasons. To understand where the genetic polymorphism 
occurs, it is important to understand the specific amino acid interactions that cause selective 
metabolism by CYP2B6. 
Bupropion’s chemical structure is a trimethylated monocyclic phenylaminoketone, shown 
in Figure 1. It is extensively metabolized to three active metabolites: hydroxybupropion by 
CYP2B6, threo-bupropion by carbonyl reductase, and erythro-bupropion by carbonyl reductase.7  
1. 2A.                    2B.         
Figure 1. 2D chemical structure of bupropion.8 Highlighted in yellow is the stereocenter.  
Figure 2. (A) Ball-and-stick model of (R)-bupropion.8 (B) Ball-and-stick model of (S)-
bupropion.9 The gray atoms represent carbon, white represents hydrogen, green represents 
chlorine, red represents oxygen, and blue represents nitrogen. 
 
CYP2B6 metabolizes bupropion to hydroxybupropion via methyl hydroxylation at the 
trimethyl, or tert-butyl, group of bupropion.6 Therefore, the trimethyl group of bupropion should 
be oriented towards the heme iron of CYP2B6 for efficient metabolism. Additionally, 
metabolism by CYP2B6 to hydroxybupropion is stereoselective.6 Bupropion is FDA-approved as 
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a racemate of (R)-bupropion and (S)-bupropion. The chemical structures of the two enantiomers 
differ only slightly in the direction of the trimethyl group, as shown in Figures 2A and 2B. (R)-
bupropion is metabolized by CYP2B6 to (R,R)-hydroxybupropion, and (S)-bupropion is 
metabolized to (S,S)-hydroxybupropion, seen in Figure 3. CYP2B6 has been shown to 
metabolize bupropion with a 3-fold greater hydroxylation of (S)-bupropion than (R)-bupropion in 
expressed CYP2B6 and 1.5-fold greater hydroxylation in human liver microsomes.6  
 
Figure 3. CYP2B6 metabolism of bupropion enantiomers through hydroxylation at the tert-butyl 
group.10 
 
However, CYP2B6 is not the only CYP isozyme that has been shown to play a role in 
metabolism. In vitro, CYP3A4 and 2E1 have metabolized bupropion at high concentrations but 
not at clinically relevant concentrations. One study found that cDNA-expressed CYP2E1 and 
3A4 had the second and third highest rates of bupropion hydroxylation. 11 In this study, at 
concentrations of 500 µM bupropion, CYP2B6 was the selective metabolizing enzyme. At less 
than 500 µM bupropion, CYP3A4 and 2E1 did not metabolize bupropion at a detectable rate, 
meaning that bupropion still has a higher affinity for CYP2B6. However, in humans with low 
CYP2B6 expression, CYP2E1 significantly contributed to metabolism at extremely high 
substrate concentrations, around 12 mM.11 The amino acid interactions between CYP2E1 and 
3A4 with bupropion could be considered to explain metabolism only at high concentrations.  
Santos 8 
 
CYP2C19, on the other hand, has been shown to metabolize bupropion in-vitro at low 
concentrations and via alternate hydroxylation pathways. 12 A study of bupropion incubation of 
cDNA-expressed CYP (rhCYP) enzymes and human liver microsomes (HLM) determined that 
CYP2C19 contributed to 70-90% of formation of metabolites 4-6, while CYP2B6 contributed to 
90% of metabolite 3 formation. Unlike CYP2E1, higher activity of CYP2C19 occurred at lower 
substrate concentrations, around 1 µM. CYP2C19 had negligible activity at high bupropion 
concentration.12 Figure 4 below shows the structures of the proposed metabolites. As seen in 
Figure 4, the site of hydroxylation by CYP2B6 differs from those of CYP2C19. 
M3 from 1 µM 
bupropion in  
rhCYP2B6 
incubations 















Site of hydroxylation: 
 
Trimethyl  
(or tert-butyl) group  
Site of hydroxylation: 
 
Methyl group 
Site of hydroxylation: 
 
Aromatic ring 
Site of hydroxylation: 
 
Aromatic ring  
Figure 4. Metabolites 3, 4, 5, and 6 with sites of hydroxylation. An in-vitro phenotyping study 
identified a total of nine bupropion metabolites (M1-M9) through incubation with c-DNA 
expressed CYPs and human liver enzymes.12  
 
In previous studies, CYP2B6 has been shown to be the major CYP enzyme involved in 
metabolizing bupropion, through hydroxylation of the trimethyl group and with significant 
stereoselectivity of the racemic drug. CYP2E1 and CYP3A4 have shown metabolism at high 
substrate concentrations, while CYP2C19 has shown metabolism at low substrate concentrations 
with different sites of hydroxylation from CYP2B6. Analyzing the amino acid interactions 
between bupropion and a CYP isozyme may help to explain why CYP2B6 is still the major 
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metabolizing isozyme, when metabolism by other isozymes could potentially occur. The purpose 
of this investigation is to use computational analysis to identify differences in binding between 
bupropion as the substrate and various CYP450 isozymes as the receptor.  
Methods 
To simulate protein-ligand docking, AutoDock Vina and Schrödinger GLIDE were used. 
Schrödinger GLIDE is a physics-based molecular docking program. In contrast, AutoDock Vina 
uses a set of physics-based definitions to create the initial state and a machine learning style 
scoring function.13, 14 Comparison of results of docking bupropion into the selected CYP 
isozymes from multiple molecular docking programs can predict the interaction of bupropion 
enantiomers with each CYP enzyme active site and predict possible important active site 
residues governing bupropion orientation relative to the heme in addition to providing a cross-
check of results from the other program by using a separate scoring function. 
The first step in simulating molecular docking in Schrödinger GLIDE was preparing the 
ligand for docking using the Maestro Ligand Preparation Wizard. This included generating 
multiple charged states at pH 7.4, including protonating the ligand for the selected pH. Next, the 
receptor, in this case CYP1A2, was prepared for docking using the Protein Preparation Wizard to 
protonate amino acids at pH 7.4 and remove the ligand and water molecules from the PDB 
structure 2HI4 downloaded from the RCSB Protein Data Bank (PDB) in the Protein Preparation 
Wizard. Part of this process included changing the oxidation state of the heme iron to +3 to 
reflect the initial oxidized state of the heme when a ligand is bound. A receptor grid was 
generated using an inner box with a dimension of 15 Å x 15 Å x 15 Å and an outer box with a 
dimension of 30 Å x 30 Å x 30 Å around a point centered in the enzyme active site. The receptor 
grid was centered above the heme iron in the known active site of each CYP enzyme. This 
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allowed for the edge of the heme to be included in the box. Ligand docking was accomplished by 
choosing the prepared ligand and receptor and using the GLIDE extra precision (XP) mode. The 
output of GLIDE represents clusters of docked poses. Following the molecular docking 
simulation, Schrödinger Maestro was used to visualize the binding orientation of bupropion, 
amino acid residues, and bonding reactions that were occurring in the between the ligand and 
amino acid residues within 5 Å of the ligand. This process was repeated for the remaining 
receptors: CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 
(Figure 5). 
With AutoDock Vina, bupropion was prepared for docking by protonating it for pH 7.4. 
Bupropion and the receptors were converted from a PDB format to a charged PDBQT format 
using AutoDockTools with a flexible ligand and rigid receptors. The same initial PDB files used 
to create inputs for the Schrödinger GLIDE experiments were used for preparing files for 
AutoDock Vina. Figure 5 shows the structure of PDB used for each isozyme for both 
Schrödinger GLIDE and AutoDock Vina. For each receptor, docking of the ligand into the 
receptor was performed using a custom Python script, the HADDOCK-Vina wrapper, written by 
Arthur Roberts at the University of Georgia. The results of docking either an (R- or S-) 
bupropion were saved to a PDBQT file. This output was converted to PDB format to be readable 
by PyMOL. For AutoDock Vina, the default settings were used. A grid of 60 Å x 60 Å x 60 Å 
was used with the grid center 10 Å above the heme iron. Results from AutoDock Vina and 
GLIDE were visualized and scored using Maestro. AutoDock Vina gives more poses than 
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Figure 5. X-ray crystal structures used for each CYP isozyme. 
These programs gave the most likely poses bupropion would have in the active site, with 
some isozymes having more ligand outputs than others. GLIDE provided (R- or S-) enantiomer 
poses, with the highest-scoring pose being the most likely metabolized enantiomer. For 
AutoDock Vina, two simulations were performed: protein-ligand docking of just (S)-enantiomer 
and protein-ligand docking of just (R)-enantiomer. Because metabolism of bupropion by 
CYP2B6 occurs when the trimethyl group is oriented towards the heme iron, the top five highest-
scoring poses could then give insight as to which enantiomer was oriented properly in the active 
site for likely metabolism. However, as mentioned in the introduction, CYP2B6 hydrolyzes the 
trimethyl group of bupropion while CYP2C19 potentially hydrolyzes the methyl group and 
aromatic ring; this investigation focused only on hydroxylation of the trimethyl group for all 
CYP isozymes. In other words, in this investigation, the proper orientation for metabolism was 
defined as the trimethyl group of bupropion pointing towards the heme iron of the CYP isozyme. 
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Additionally, the types of contacts between atoms of the ligand and those of the CYP 
isozyme on GLIDE and AutoDock Vina were categorized as “good,” “bad,” and “ugly.” The 
formula used to define the type of contact is as follows: C= D12/(R1 + R2), where C is for cutoff 
ratio, D12 is the distance between atomic centers 1 and 2, and R1 and R2 are the radii of atomic 
centers 1 and 2, respectively. For analysis of AutoDock Vina and GLIDE results using Maestro, 
the default value for a “good” contact was 1.3 Å, 0.89 Å for a “bad” contact, and 0.75 Å for an 
“ugly” contact. The smaller contact cutoff ratio meant that the distance between the two atomic 
centers was too close and could cause steric strain. Distances greater than C(good) were not 
marked, and distances less than C(good) but greater than C(bad) were marked as “good.” These 
ratios excluded hydrogen bonds and salt bridges for both programs. Since results from both 
AutoDock Vina and GLIDE were analyzed using the same criteria, the number of “bad” and 
“ugly” interactions between the ligand and receptor could be compared between the two 
programs. In an actual enzyme active site, “bad” and “ugly” interactions could mean that the 
ligand won’t stay in the output orientation, there might be a change in binding affinity, or there 
might be a change in orientation in the active site. It likely means the ligand-protein interaction is 
unstable in this binding orientation and will not stay in the given output position. The quantity of 
these “bad” and “ugly” interactions between the ligand and amino acids of the enzyme active site 
could be compared between the (S)-bupropion and (R)-bupropion to see if one enantiomer might 








AutoDock Vina gave nineteen poses for each isozyme, but GLIDE gave varying amounts 
of outputs. CYPs 1A2, 2A6, 2B6, 2C8 and 2C9 had four outputs in GLIDE. CYPs 2C19, 2D6, 
and 2E1 only had one, while CYP3A4 had seventeen. The number of outputs only represents the 
number of clusters and different output methods used by each program. The output for both 
molecular docking programs is a set of clustered poses represented by one result per cluster. 
AutoDock Vina will typically give close to the maximum number of outputs designed into the 
program, which is twenty.  
In CYP1A2, both AutoDock Vina and GLIDE gave outputs in a single area of the 
enzyme active site. In AutoDock Vina, the two highest-scoring poses for both enantiomers had 
the trimethyl pointed towards the heme. In GLIDE, which gave four outputs, the highest-scoring 
pose was an (R)-enantiomer with the trimethyl pointed towards the heme. Meanwhile, the second 
highest-scoring pose was an (S)-enantiomer with trimethyl pointed away from the heme and also 
had four more “bad” interactions with the receptor than does the (R)-enantiomer. As mentioned 
in the introduction, with “bad” interactions, the ligand is not stable in that position and could 
cause various changes in the active site. Therefore, the (R)-enantiomer ligands had proper 
orientation for binding in both programs, and it was the highest-scoring pose in GLIDE. These 
results indicate that binding of bupropion to CYP1A2 and orientation of the tert-butyl group 
toward the heme iron are possible, but this is not sufficient for CYP1A2-mediated metabolism. 
In CYP2A6, it was the (S)-enantiomer ligands that had the tert-butyl group bind toward 
the heme for results from both programs, but results from both programs showed multiple “bad” 
interactions between the ligand and receptor. In AutoDock Vina, all nineteen output poses had 
around ten “bad” interactions for both the (R- and S-) enantiomers. In addition, the two highest-
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scoring poses for (R)-bupropion had trimethyl pointed away from the heme, while the two 
highest-scoring poses for (S)-bupropion had trimethyl towards the heme. Simulations using 
GLIDE provided similar results. The highest-scoring pose was the (S)-enantiomer, and it had the 
trimethyl group towards the heme and had seven “bad” interactions with the active site amino 
acids. The second highest pose in GLIDE was an (R)-enantiomer, and it also had the trimethyl 
group towards the heme, but it had fifteen bad interactions with the active site amino acids. 
Figure 6 shows how these interactions were visualized through Maestro. Both AutoDock Vina 
and GLIDE showed multiple “bad” interactions between the ligand molecule and the receptor, no 
matter what the enantiomer. This suggests that maybe a moving active site, rather than the static 
one used in this investigation, may decrease the number of “bad” interactions. Similarly to 
CYP1A2, bupropion is predicted to bind in the CYP2A6 active site for productive hydroxylation 
of the trimethyl group, but CYP2A6-mediated metabolism is not observed in in vitro or in vivo 
studies. 
         
Figure 6. GLIDE outputs for CYP2A6 and bupropion visualized through Maestro. The left 
ligand is (S)-bupropion. On the right is (R)-bupropion. The heme iron is the molecule at the 
bottom of both images. The orange dashed lines represent “bad” interactions, with there being 
seven seen for the (S)-enantiomer and fifteen for the (R)-enantiomer. The blue dashed lines 





As previously described, stereoselective metabolism by CYP2B6 occurs with a 3-fold 
greater hydroxylation of (S)-bupropion than (R)-bupropion. Results from our molecular docking 
simulations agree with the experimental results. The highest scoring pose in GLIDE was an (R)-
enantiomer, but it was stabilized by only one interaction, a hydrogen bond, with the receptor. 
Meanwhile, the second highest scoring pose was an (S)-enantiomer that was stabilized by two 
interactions with the receptor, two π-π interactions, as shown in Figure 7. Since π-π interactions 
can have similar stabilizing effect to hydrogen bonds at roughly the same energy value, the 
greater number of interactions likely creates a more stable site for metabolism of the (S)-
enantiomer than of the (R)-enantiomer. Unlike with GLIDE, in AutoDock Vina, there appeared 
to be two distinct populations of output poses (Figure 8). One population was bound directly 
above the heme iron. The poses in this area were likely to be metabolized. A second set of 
outputs was oriented diagonally above the heme, and the site of metabolism is not likely to be 
close enough to the heme iron for hydroxylation to occur. The highest-scoring (S)-bupropion 
output populated the area closer to the heme, although its trimethyl group was not towards the 
heme iron as previously mentioned. The second highest-scoring (S)-bupropion pose was in the 
area farther from the heme, and the third- and fourth- highest-scoring poses also had trimethyl 
away from the heme. These results from AutoDock Vina did not have trimethyl towards the 
heme for metabolism, as had been shown in previous studies and GLIDE. However, the results 
from AutoDock Vina do support (S)-bupropion being more likely to be metabolized than (R)-
bupropion in terms of distance to the heme iron. For (R)-bupropion, the highest-scoring pose was 
in the pocket farther from the heme, and it was not until the fifth highest-scoring pose that the 
ligand was in the area closer to the heme. The highest-scoring poses for (R- and S-) enantiomers 
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are shown in Figure 9. (S)-bupropion had a more optimal binding orientation than (R)-bupropion 
in both programs.  
 
Figure 7. CYP2B6 highest-scoring pose from GLIDE visualized from PyMol. This image shows 
phenylalanine 296 (depicted in pink) and phenylalanine 206 (depicted in pink) of CYP2B6 
stabilizing the (S)-bupropion pose (depicted in silver) with pi bonds (depicted as black dashed 
lines). The heme iron is shown in red.   
   
 
Figure 8. CYP2B6 all (R)-enantiomer output poses from AutoDock Vina visualized from 
Maestro. When all nineteen poses, depicted in green, were selected and overlaid above one 
another, there appeared to be two areas where poses were bound in the active site. This same 
observation occurred with the (S)-enantiomer poses for AutoDock Vina as well.  
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Figure 9. CYP2B6 highest-scoring poses from AutoDock Vina for (S)-bupropion on the left and 
(R)-bupropion on the right visualized from Maestro. The trimethyl group pointed away from the 
heme iron for (S)-bupropion, but (R)-bupropion was not anywhere close to the heme for 
hydroxylation of its trimethyl group. 
 
In CYP2C8, AutoDock Vina also gave outputs with ligands binding in two distinct 
locations of the receptor: one farther from the heme, which was in the substrate access channel, 
and one near the heme (Figure 10). The first six highest-scoring poses for (R)-enantiomers and 
the first ten highest-scoring poses for (S)-enantiomers were in the substrate access channel. 
Affinity for that area might be too high, not allowing the ligand to move closer to the heme. 
Distances in angstroms were not quantified between poses in either populated area of the binding 
pocket and the heme iron in AutoDock Vina, since visually and relative to the poses closer to the 
heme, those poses in the substrate access channel were not close enough to the heme iron to be 
metabolized (Figure 10). For reference, the length of a bupropion molecule is about 16 Å. On the 
other hand, the four poses given by GLIDE were not in the substrate access channel but in the 
area that was closer to the heme. Again, the highest-scoring pose was an (R)-enantiomer with the 
trimethyl towards the heme. Although GLIDE did not show any outputs by the substrate access 
channel, it might have been due to the simulation settings. The box parameter around the 
receptor where binding could occur might have been too small and not detected another binding 




simulation, but those of AutoDock Vina show that bupropion might not be getting close enough 
to the heme iron for it to hydroxylate bupropion’s trimethyl group. While the (R)-enantiomer in 
AutoDock Vina had its seventh highest-scoring pose in the pocket closer to the heme, it wasn’t 
until the eleventh highest-scoring pose that (S)-enantiomer bound closer to the heme. 
Additionally, in GLIDE, the highest-scoring pose was an (R)-enantiomer with trimethyl towards 
the heme group. As shown by both AutoDock Vina and GLIDE, the (R)-enantiomer could be the 
one more likely metabolized by CYP2C8.  The (S)-enantiomer might not fit well in the active 
site. Once again, these results suggest that the metabolism of bupropion by this CYP isozyme is 
not governed solely by the binding of the ligand to the enzyme, since binding of bupropion to 
CYP2C8 is possible in silico. 
 
Figure 10. CYP2C8 all (R)-enantiomer output poses from AutoDock Vina visualized from 
Maestro. When all nineteen poses, depicted in green, were selected and overlaid above one 
another, there appeared to be two areas where poses were bound in the active site. The poses 
populating the area farther from the heme are in the substrate access channel. This same 
observation occurred with the (S)-enantiomer poses for AutoDock Vina as well. 
 
In CYP2C9, both AutoDock Vina and GLIDE gave similar results in that bupropion did 
not bind anywhere near the heme. The nineteen (R- and S-) enantiomer poses in AutoDock Vina 
were bound in two distinct populations that were both far from the heme, as shown in Figure 11. 
The highest-scoring poses for (R- and S-) bupropion were both far from the heme (Figure 12). 
R 
area closer 
to the heme  
area farther 
from the heme  
Santos 19 
 
These distances in angstroms to the heme iron were not quantified since visually, these poses 
were not anywhere close to the heme for metabolism to occur. GLIDE detected only one binding 
area, but it was also far from the heme. The top pose in GLIDE, an (S)-bupropion, was stabilized 
by three interactions with the receptor as shown in Figure 13, but it was still not near the heme. It 
is possible that bupropion is not metabolized as significantly as CYP2B6 by CYP2C9 because it 
is being stabilized in an area of the binding pocket that is not close enough to the heme. As for 
stereoselective metabolism, the highest-scoring pose in GLIDE was an (S)-enantiomer and was 
stabilized by two more interactions with the receptor than did the (R)-enantiomer, the second-
highest scoring pose. In AutoDock Vina, the first three (S)-enantiomer poses had less “bad” 
interactions with the receptor than did the first three (R)-enantiomer poses. Having less “bad” 
interactions means more stability in that orientation in the active site. The (S)-enantiomer in both 
programs had a more optimal orientation in the receptor. 
 
Figure 11. CYP2C9 all (R)-enantiomer output poses from AutoDock Vina visualized from 
Maestro. When all nineteen poses, depicted in green, were selected and overlaid above one 
another, there appeared to be two areas where poses were bound in the active site. This same 




      





Figure 13. (S)-bupropion pose from GLIDE visualized from PyMol. This image shows 
phenylalanine-69 (depicted in pink) and phenylalanine-100 (depicted in pink) of CYP2C9 
stabilizing the (S)-bupropion pose from GLIDE (depicted in teal) with pi-bonding and 
phenylalanine-476 (depicted in pink) with a pi-cation interaction. These bonds are represented by 
black dashed lines. The distance between the stereocenter of bupropion and the heme iron is 
13.5Å, as estimated by PyMol. 
 
In CYP2C19, bupropion was also bound to multiple populations (Figure 14). In 
AutoDock Vina, the highest-scoring (R)-enantiomer pose had the trimethyl group away from the 
heme. Its second highest-scoring (R)-enantiomer pose had the trimethyl towards the heme but not 




heme. As for the (S)-enantiomer poses, the top five highest-scoring poses had trimethyl near the 
heme but not at an optimal angle for metabolism. The highest-scoring poses from AutoDock 
Vina are shown in Figure 15. As for GLIDE, it only gave one output, which was an (S)-
enantiomer, but its trimethyl group was away from the heme. These findings support the study 
that incubated bupropion with cDNA-expressed CYP enzymes and human liver microsomes.12 
CYP2C19 was determined to metabolize bupropion in vitro via alternate hydroxylation 
pathways. Hydroxylation occurred at the methyl and aromatic groups, not the trimethyl group 
that is metabolized by CYP2B6 (Figure 4). The findings from our simulations showed that the 
highest-scoring poses for either enantiomer in both programs did not have the trimethyl group 
either pointed towards or at an optimal angle to the heme iron. The output poses are oriented so 
the methyl or aromatic groups would be metabolized. However, further analysis was not 
performed, since hydroxylation of the tert-butyl group was not likely in these poses.  Simulated 
molecular docking looking only at the orientation of the ligand in the active site cannot solely 
explain why CYP2B6 hydroxylation at the trimethyl group occurs more frequently than 
CYP2C19 hydroxylation at the methyl and aromatic groups. The previous study did mention that 
this alternate metabolism via CYP2C19 occurred in vitro at low concentration, around 1 µM 
bupropion. It could be that at this concentration, crowding at the active site does not occur so that 
the hydroxylated groups are the ones directed towards the heme iron. Clinically, bupropion 
would be given at a much higher concentration that 1 µM so that if concentration does play a 
factor in which isozyme significantly metabolizes bupropion, it would be CYP2B6, which could 
accommodate and metabolize bupropion above 1 µM. One possible explanation for this 




Overall, simulated molecular docking in this investigation has shown that bupropion 
could bind in an area far enough from the heme iron to not be metabolized and that bupropion 
likely binds to the active site with the trimethyl group either pointed or angled away from the 
heme iron. Other considerations, such as ligand concentration and alternate hydroxylation 
pathways could better answer the in vivo preferential metabolism of bupropion by CYP2B6 over 
CYP2C19. 
 
Figure 14. CYP2C19 all (R)-enantiomer output poses from AutoDock Vina visualized from 
Maestro. When all nineteen poses, depicted in green, were selected and overlaid above one 
another, there appeared to be two areas where poses were bound in the active site. 
      
      
Figure 15. The highest-scoring (S- and R-) bupropion poses from AutoDock Vina visualized 
from Maestro. The trimethyl group of (S)-bupropion is not at an optimal angle directly above the 











In CYP2D6, AutoDock Vina poses populated three different areas of the binding site. 
Similar to CYP2B6, CYP2C8, CYP2C9, and CYP2C19, the poses from the areas farther from 
the heme iron were not quantified in angstroms, since visually, the site of metabolism was farther 
away from the heme than the length of a bupropion molecule, around 16 Å as previously 
mentioned. Twelve of the nineteen (R)-bupropion poses were in an area near the heme, but only 
four of those twelve poses had trimethyl towards the heme. Likewise, for the (S)-enantiomer 
poses, only four of the nineteen poses were near the heme with trimethyl pointing towards the 
heme. GLIDE gave only one output, which was an (S)-enantiomer, but trimethyl was away from 
the heme. It is possible that bupropion is not metabolized by CYP2D6 because it binds with the 
trimethyl group away from the heme. As for this receptor’s preferred enantiomer, although the 
highest-scoring (R)-enantiomer pose in AutoDock Vina had trimethyl towards the heme, while 
the highest-scoring (S)-enantiomer had trimethyl away from the heme, the highest-scoring (R)-
enantiomer also had six more “bad” interaction with the receptor than did the highest-scoring 
(S)-enantiomer. Also, given that the only output by GLIDE was an (S)-enantiomer, overall, the 
(S)-enantiomer had a more favorable binding orientation that did the (R)-enantiomer. 
In CYP2E1, using the contact cutoff ratios to analyze “bad” interactions between the 
ligand and receptor provided similar results from both AutoDock Vina and GLIDE. In GLIDE, 
the one output pose for bupropion, which was the (S)-enantiomer, had over ten “bad” interactions 
with the CYP2E1 active site residues. Its trimethyl group was also away from the heme, as 
shown in Figure 16. In AutoDock Vina, the five highest-scoring ligand poses for the (R)-
enantiomer had a range of seven to thirteen “bad” contacts and one to five “ugly.” The five 
highest-scoring (S)-enantiomer poses had five to nine “bad” and two to three “ugly” contacts. It’s 
likely that the small active site within CYP2E1 created steric strain between the atoms of its 
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residues and those of bupropion. The other isozymes did not have as much “ugly” contacts with 
bupropion as did CYP2E1. As for stereoselective metabolism, since the only output in GLIDE 
was an (S)-enantiomer and since the highest-scoring (S)-enantiomer had less “bad” contacts with 
the active site residues than did the highest-scoring (R)-enantiomer, CYP2E1 may preferentially 
metabolize (S)-bupropion. Using simulated molecular docking to analyze amino acid interactions 
between bupropion and the isozyme, however, might not be enough to answer why bupropion 
metabolism still occurs more with CYP2B6 than CYP2E1. As mentioned in the introduction, one 
study found that in humans with low CYP2B6 expression, CYP2E1 significantly contributed to 
metabolism at extremely high substrate concentrations, around 12 mM.11 It could be that at such 
high concentrations, the bupropion molecules crowd in the active site and push against one 
another as they bind and come off, to the point where some molecules are eventually pushed into 
an optimal position to be metabolized by the heme iron.  
 
 
Figure 16. The only pose in GLIDE for CYP2E1 visualized from PyMol. (S)-bupropion 
(depicted in teal) is stabilized by phenylalanine-298 (depicted in pink) with a pi-bond. The 




In CYP3A4, AutoDock Vina gave nineteen outputs bound in two distinct areas of the 
active site, one closer to the heme and one farther away (Figure 17). Again, as with CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, and CYP2D6, the poses in the areas farther from the heme iron 
were not quantified in angstroms, since visually, they were not anywhere near the heme to be 
metabolized. For the (R)-enantiomer, the fourth highest-scoring pose had the highest affinity to 
populate the area closer to the heme, but even this pose had the trimethyl group away from the 
heme. Similarly, for the (S)-enantiomer, the fifth highest-scoring pose had the highest affinity to 
populate the area closer to heme but its trimethyl group was also away from the heme. 
Additionally, the poses that were in the pocket closer to the heme were oriented too closely to the 
heme that the ligand would interfere with oxygen binding to the heme iron, preventing 
metabolism. Therefore, for AutoDock Vina, poses were either bound far from the heme, had the 
trimethyl away from the heme, or were not angled properly towards the heme for metabolism.  
GLIDE found different results. Its seventeen poses were bound to only one area of the active site, 
as shown by one pose in Figure 18. Except for the ninth highest-scoring pose, all of them had 
trimethyl towards the heme. However, like in CYP2C8, the box parameter might have been too 
small to detect another binding site outside of its dimensions. Otherwise, it might have found two 
areas in the binding site the way AutoDock Vina did. AutoDock Vina showed that CYP3A4 has 
a large active site with two areas for binding in the active site. Just like with CYP2B6, CYP3A4 
had two possible areas within the active site for binding, so this reasoning cannot explain why 
bupropion is preferentially metabolized by CYP2B6 over CYP3A4. A previous study mentioned 
in the introduction found that in vitro, CYP3A4 and 2E1 have metabolized bupropion at high 
concentrations (greater than 500 µM bupropion) but not at clinically relevant concentrations.2 
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CYP3A4 has a large active site, so at high concentrations, it could possibly accommodate more 
than one ligand molecule which could push each other to be in the proper orientation near the 
heme. Similar to how high ligand concentrations can push ligands into a proper orientation in the 
small CYP2E1 active site, high ligand concentrations might also do the same thing in the large 
CYP3A4 active site. As with CYP2E1, simulated molecular docking to analyze the orientation of 
bupropion in the active site could not completely explain in vivo selective metabolism by 
CYP2B6 over CYP3A4. 
 
Figure 17. CYP3A4 all (R)-enantiomer output poses from AutoDock Vina visualized from 
Maestro. When all nineteen poses, depicted in green, were selected and overlaid above one 
another, there appeared to be two areas where poses were bound in the active site. This same 
observation occurred with the (S)-enantiomer poses for AutoDock Vina as well. 
R 
area farther 
from the heme  
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Figure 18. The second pose of (S)-bupropion from GLIDE visualized from PyMol. The 




Overall, the following CYPs gave outputs in which the (S)-enantiomer was stabilized by 
more interactions with the receptor than was the (R)-enantiomer or had the trimethyl group 
pointed towards the heme iron for hydroxylation: CYP2A6, CYP2B6, CYP2C9, CYP2D6, 
CYP2E1, and CYP3A4. This computational analysis conferred with the stereoselective 
metabolism of (S)-bupropion by CYP2B6 found in another study.6 Meanwhile, the (R)-
enantiomer had a more optimal binding orientation in CYP1A2 and CYP2C8. CYP2C19 did not 
have trimethyl pointed towards the heme in both programs, but because it likely does not 
hydroxylate the trimethyl group, the orientation of the trimethyl group towards the heme iron 
could not be used as a standard to compare which enantiomer had a more optimal orientation in 
the active site to be stereoselectively metabolized.  
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The following isozymes had poses bind in distinct areas of the active site: CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. It could be that for these isozymes, 
ligands were more likely to bind in the area farther from the heme, although this phenomenon 
was shown to happen in CYP2B6 as well.  
The protein-ligand simulation AutoDock Vina and GLIDE explained the reason why 
some isozymes have not clinically been shown to metabolize bupropion. With CYP2C8, 
AutoDock Vina showed the five highest-scoring poses for both enantiomers were far from the 
heme. With CYP2C9, all ligand poses from both programs were also far from the heme. With 
CYP2C19, ligand poses were far from the heme, did not have trimethyl towards the heme, or 
were near the heme but not at a proper angle for metabolism. However, given that CYP2C19 has 
been shown to metabolize bupropion at relatively low substrate concentrations, around 1 µM, 
and at alternate hydroxylation sites,12 there could be another explanation for this metabolism that 
is not explained by specific amino acid interactions or not captured by simulated molecular 
docking. With CYP2D6, in the majority of poses for both programs, the trimethyl was away 
from the heme. With CYP2E1, its small active site created over ten “bad” interactions between 
the ligand and receptor for both programs. With CYP3A4, the large active site could possibly 
accommodate more than one ligand molecule. Although this simulation eliminated these 
isozymes, it did not find specific interactions that could explain why bupropion’s metabolism is 
mainly mediated by CYP2B6.  
There were several limitations in this study. One limitation is that this study looked only 
at the orientation of bupropion’s trimethyl group towards the heme iron group for proper 
hydroxylation and metabolism. However, CYP2C19 could potentially hydroxylate the methyl 
and aromatic groups. This investigation did not look at other groups of bupropion that could also 
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be hydroxylated by the heme iron. In future studies, the orientation of other groups towards the 
heme iron could be evaluated. 
In the future when using GLIDE, a larger box parameter could be used. This might allow 
the detection of two areas for binding in the active site in CYP2C8 and CYP3A4 that were 
identified by AutoDock Vina but not by GLIDE. This allows for a more one-to-one comparison 
between the two docking programs. 
A flexible receptor and ligand could also be used in the future. In CYP2E1, simulating 
both to be flexible could change the amount of “bad” interactions between the ligand and 
receptor in the small active site.  
Another limitation occurred given the nature of simulated molecular docking. In 
molecular docking without a solvent, as was the case in this investigation, the simulation consists 
of one molecule of substrate interacting with one molecule receptor. This is used to predict the 
behavior of what would happen in an actual interaction. There is no concentration of substrate 
used as molecular docking describes the formation of a complex of the enzyme when the ligand 
occupies the binding site. On the other hand, in a clinical setting, the interaction occurs in a 
solution. A solution can predict the likelihood of interaction and how fast substrates are being 
bound and unbound for likely metabolism. Current computational methods do not have the 
capability to simulate this type of docking well. 
Furthermore, the CYP enzyme catalytic cycle is quite complex, as shown in Figure 19. 
Molecular docking only represents binding of the substrate to the enzyme (Step 1 to Step 2). 
Conformational changes in the CYP enzyme structure due to NADPH:cytochrome P450 
oxidoreductase binding and electron transfer to the CYP enzyme (Step 2 to Step 3; Step 4 to Step 
5a) and cytochrome b5 binding to the CYP enzyme also contribute to specificity of substrate 
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metabolism. These conformational changes are not taken into account by molecular docking 
programs, even if induced fit docking or flexible receptors are used. 
 
Figure 19. The CYP enzyme catalytic cycle. 
 
Schrödinger GLIDE and Maestro also identified only the amino acid residues of the 
receptor that had the following interactions with bupropion’s amino acid residues: hydrogen 
bonds, π-π stacking, pi-cation, and halogen bonds. This was done instead of identifying the 
receptor’s active site residues that were within 5Å of the bound ligand. This method might have 
missed amino acid residues in the receptor that are key players in stabilizing the binding 
orientation of bupropion. In the future, when visualizing docking using Maestro, all receptor 
residues within 5Å of the bound ligand should be highlighted to look for possible interactions, 
instead of focusing solely on the receptor residues with the specific aforementioned interactions. 
These improvements could provide more information on the specific interactions between 
racemic bupropion and this panel of nine cytochrome P450s. 
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Overall, this simulated molecular docking investigation visualized amino acid 
interactions, distances between the ligand and heme iron, and orientation of the ligand molecule 
in the active site. It was able to show how one enantiomer might be more stable in an active site 
than the other enantiomer. It offered some answers as to why metabolism by certain isozymes 
might not occur as frequently as another isozyme. It had several limitations but could still be 
used to eliminate some isozymes. Other concepts like ligand concentration, alternate 
hydroxylation pathways, conformational changes within the CYP enzyme catalytic cycle, and 
alternate methods to use Schrödinger GLIDE and AutoDock Vina might offer other answers as 
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